Article

CSF-1 drops demonstrate efficacy, safety in clinical studies for treatment of presbyopia

Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.


Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
AAO 2024: Weijie Violet Lin, MD, discusses risk factors for epithelium-off cross-linking
© 2025 MJH Life Sciences

All rights reserved.